Abivax SA
ABVX145.310USD
+6.960+5.03%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Abivax SA Company
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Abivax SA Info
Ticker SymbolABVX
Company nameAbivax SA
IPO dateJun 26, 2015
CEOde Garidel (Marc)
Number of employees- -
Security typeDepository Receipt
Fiscal year-end- -
Address7-11 Boulevard Haussmann
CityPARIS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryFrance
Postal code75009
Phone33153830963
Websitehttps://www.abivax.com/
Ticker SymbolABVX
IPO dateJun 26, 2015
CEOde Garidel (Marc)
Company Executives of Abivax SA
Name
Name/Position
Position
Shareholding
Change
,
,
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Kevin Shan
Kevin Shan
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Ms. Sophie Lacourrege
Ms. Sophie Lacourrege
Vice President, HR Business Partner, Engagement and Culture
Vice President, HR Business Partner, Engagement and Culture
--
--
Nadege Briancon-eris
Nadege Briancon-eris
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Jennifer Fine
Jennifer Fine
Senior Vice President, Global Head - HEOR and RWE
Senior Vice President, Global Head - HEOR and RWE
--
--
Douglas Jacobstein
Douglas Jacobstein
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
Mary Mantock
Mary Mantock
Senior Vice President, Global Head - Regulatory Affairs
Senior Vice President, Global Head - Regulatory Affairs
--
--
Mr. Patrick Malloy
Mr. Patrick Malloy
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
,
,
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Kevin Shan
Kevin Shan
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Ms. Sophie Lacourrege
Ms. Sophie Lacourrege
Vice President, HR Business Partner, Engagement and Culture
Vice President, HR Business Partner, Engagement and Culture
--
--
Nadege Briancon-eris
Nadege Briancon-eris
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Jennifer Fine
Jennifer Fine
Senior Vice President, Global Head - HEOR and RWE
Senior Vice President, Global Head - HEOR and RWE
--
--
Douglas Jacobstein
Douglas Jacobstein
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
TCG Crossover Management, LLC
9.67%
UBS Financial Services, Inc.
6.06%
Darwin Global Management Ltd
4.30%
Point72 Asset Management, L.P.
3.98%
Cormorant Asset Management, LP
2.65%
Other
73.34%
Shareholders
Shareholders
Proportion
TCG Crossover Management, LLC
9.67%
UBS Financial Services, Inc.
6.06%
Darwin Global Management Ltd
4.30%
Point72 Asset Management, L.P.
3.98%
Cormorant Asset Management, LP
2.65%
Other
73.34%
Shareholder Types
Shareholders
Proportion
Hedge Fund
33.85%
Investment Advisor
22.65%
Investment Advisor/Hedge Fund
8.69%
Research Firm
2.98%
Venture Capital
2.18%
Private Equity
1.77%
Pension Fund
1.00%
Other
26.88%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
216
53.64M
52.23%
+104.02K
2025Q3
210
53.54M
52.22%
+19.70M
2025Q2
81
30.74M
57.27%
-1.09M
2025Q1
75
31.82M
50.24%
-38.10K
2024Q4
68
29.91M
44.59%
+2.48M
2024Q3
54
27.43M
45.93%
-700.83K
2024Q2
51
33.52M
46.25%
-227.21K
2024Q1
46
28.78M
34.33%
+7.18M
2023Q4
33
27.04M
1.75%
+20.54M
2023Q3
1
5.40M
0.00%
--
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
TCG Crossover Management, LLC
6.06M
8.23%
--
--
Jun 30, 2025
Cormorant Asset Management, LP
2.13M
2.9%
--
--
Jun 30, 2025
Caligan Partners, LP
1.67M
2.28%
+405.28K
+31.93%
Jun 30, 2025
Fidelity Management & Research Company LLC
1.01M
1.38%
+75.30K
+8.03%
Aug 31, 2025
Adar1 Capital Management LLC
3.07M
4.17%
+861.32K
+38.97%
Jun 30, 2025
Octagon Capital Advisors LP
1.27M
1.72%
+37.00K
+3.01%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Simplify Health Care ETF
2.86%
Harbor Health Care ETF
0.7%
Fidelity Nasdaq Composite Index ETF
0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
0%
Innovator IBD Breakout Opportunities ETF
0%
Simplify Health Care ETF
Proportion2.86%
Harbor Health Care ETF
Proportion0.7%
Fidelity Nasdaq Composite Index ETF
Proportion0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0%
Innovator IBD Breakout Opportunities ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Abivax SA?
The top five shareholders of Abivax SA are:
TCG Crossover Management, LLC holds 6.06M shares, accounting for 8.23% of the total shares.
Cormorant Asset Management, LP holds 2.13M shares, accounting for 2.90% of the total shares.
Caligan Partners, LP holds 1.67M shares, accounting for 2.28% of the total shares.
Fidelity Management & Research Company LLC holds 1.01M shares, accounting for 1.38% of the total shares.
Adar1 Capital Management LLC holds 3.07M shares, accounting for 4.17% of the total shares.
TCG Crossover Management, LLC holds 6.06M shares, accounting for 8.23% of the total shares.
Cormorant Asset Management, LP holds 2.13M shares, accounting for 2.90% of the total shares.
Caligan Partners, LP holds 1.67M shares, accounting for 2.28% of the total shares.
Fidelity Management & Research Company LLC holds 1.01M shares, accounting for 1.38% of the total shares.
Adar1 Capital Management LLC holds 3.07M shares, accounting for 4.17% of the total shares.
What are the top three shareholder types of Abivax SA?
The top three shareholder types of Abivax SA are:
TCG Crossover Management, LLC
UBS Financial Services, Inc.
Darwin Global Management Ltd
TCG Crossover Management, LLC
UBS Financial Services, Inc.
Darwin Global Management Ltd
How many institutions hold shares of Abivax SA (ABVX)?
As of 2025Q4, 216 institutions hold shares of Abivax SA, with a combined market value of approximately 53.64M, accounting for 52.23% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 0.00%.
What is the biggest source of revenue for Abivax SA?
In --, the -- business generated the highest revenue for Abivax SA, amounting to -- and accounting for --% of total revenue.
